Results 151 to 160 of about 113,188 (264)

Development and <i>in vivo</i> evaluation of novel humanized CD19 CAR-T cells for advanced B cell malignancies. [PDF]

Front Immunol
Andrade CO, Bezerra MRL, Sousa IG, Correia EM, Lima AJF, Abdo L, Aragão EAA, Araujo RPDS, Pinheiro DP, Studart IC, Steimbach JV, Pretti MA, Furtado GP, Lourenzoni MR, Brigido MM, Maranhão AQ, Bonamino MH.   +16 more
europepmc   +1 more source

Defining Composition–Cytokine Relationships Enables the Design of Lipid Nanoparticles with Programmed Immunogenicity

Small, EarlyView.
Lipid nanoparticle composition governs distinct cytokine programs through the interplay of ionizable and polyethylene glycol‐conjugated (PEGylated) lipids. In vitro profiling, design of experiments (DoE) modeling, and in vivo validation reveal how formulation can tune reactogenicity‐associated pathways, while transgene expression remains the strongest ...
Adam Alexander Walters, Belal I. Hanafy, Chuan‐En Lu, Sara Marelli, Alaa Zam, Kai Liu, Rachel E. Foreman, Ramesh Soundararajan, Philippe Collin, Lennart Lindfors, Alan Sabirsh, Mariarosa Mazza, Khuloud T. Al‐Jamal, Stephanie M. Bates, George Thom, Jan Rehwinkel, Alexander N Kapustin   +16 more
wiley   +1 more source

Anti-CD19 monoclonal antibody for systemic lupus erythematosus and neuromyelitis optica spectrum disorder. [PDF]

Lupus Sci Med
Gonzalez Manrique P, Ayoub I, Gyang T, Lin J.   +3 more
europepmc   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma. [PDF]

J Immunother Cancer
Wang L, Fang C, Zheng Y, Xu Y, Huang W, Zhao W, Wang Y, Xia J, Tan K, Wang L, Peng H, Guo X, Wang S, Wang L, Liu L, Qiao J, Meng X, He Z, Wen Z, Yu C, Mei J, Wang H, Li Y, Yu L.   +23 more
europepmc   +1 more source

immunoHuMiX: A personalizable gut‐on‐chip model for unraveling human microbiome–immune interactions

VIEW, EarlyView.
The study introduces a personalized gut model that brings together human immune cells and intestinal cells to better mimic how the body interacts with microbes. This system successfully maintained both human cells and a 17‐strain probiotic community, showing consistent immune responses across different donors.
Charlotte De Rudder, Kacy Greenhalgh, Joanna Baginska, Camille Martin‐Gallausiaux, Léa Grandmougin, Rémy Villette, Mara Lucchetti, Bérénice Hansen, Marek Ostaszewski, Viacheslav A. Petrov, Koji Atarashi, Lena Weidert, Audrey Frachet Bour, Dominik Ternes, Javier Ramiro‐Garcia, Antoine Malabirade, Takeshi Tanoue, Marc Mac Giolla Eain, Elisabeth Letellier, Matthew Barrett, Jérôme Lacombe, Frederic Zenhausern, Coralie Guérin, Markus Ollert, Carole Seguin‐Devaux, Kenya Honda, Paul Wilmes   +26 more
wiley   +1 more source

Differential cytokine architecture in patients treated with CART19 versus CART22. [PDF]

J Immunother Cancer
Diorio C, Shraim R, Thadi A, Frank-Kamenetskii A, Uppuluri L, Klinghoffer H, Martinez Z, Babu A, Myers RM, Fraietta JA, Hughes A, Sussman J, Xu J, McClory SE, Mueller K, Perazzelli J, Vella LA, Henrickson SE, Ruella M, Behrens EM, DiNofia AM, Burkhardt JK, Maude SL, Canna S, Tan K, Grupp S, Teachey DT.   +26 more
europepmc   +1 more source

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

Chimeric Antigen Receptor T-Cell Revolution Remodeling Immunity to Conquer Autoimmune Disease. [PDF]

Research (Wash D C)
Shao W, Liu J, Sun M, Yu D.
europepmc   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source